CRIS Current Research Information System

CATTINA, FEDERICA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.835
AS - Asia 2.530
EU - Europa 2.093
AF - Africa 171
SA - Sud America 142
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 2
Totale 7.778
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.793
SG - Singapore 709
CN - Cina 662
GB - Regno Unito 600
VN - Vietnam 589
SE - Svezia 356
DE - Germania 266
IT - Italia 208
HK - Hong Kong 190
FR - Francia 151
IN - India 140
RU - Federazione Russa 114
BR - Brasile 91
IE - Irlanda 79
NL - Olanda 72
CH - Svizzera 57
ZA - Sudafrica 56
TG - Togo 44
EE - Estonia 42
JP - Giappone 38
NG - Nigeria 37
BD - Bangladesh 36
FI - Finlandia 32
UA - Ucraina 31
CA - Canada 27
AR - Argentina 26
PH - Filippine 21
BG - Bulgaria 19
GR - Grecia 18
JO - Giordania 18
CI - Costa d'Avorio 17
IR - Iran 17
BE - Belgio 16
KR - Corea 16
IQ - Iraq 15
TH - Thailandia 13
TR - Turchia 12
MX - Messico 11
TW - Taiwan 9
AT - Austria 8
ES - Italia 7
LB - Libano 7
UZ - Uzbekistan 7
ID - Indonesia 6
PK - Pakistan 6
PL - Polonia 6
SA - Arabia Saudita 6
AU - Australia 5
CL - Cile 5
CO - Colombia 5
CZ - Repubblica Ceca 4
EC - Ecuador 4
EG - Egitto 4
KZ - Kazakistan 4
SC - Seychelles 4
AE - Emirati Arabi Uniti 3
PY - Paraguay 3
VE - Venezuela 3
GY - Guiana 2
MA - Marocco 2
NI - Nicaragua 2
OM - Oman 2
PE - Perù 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AO - Angola 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
CR - Costa Rica 1
DZ - Algeria 1
ET - Etiopia 1
EU - Europa 1
KE - Kenya 1
MK - Macedonia 1
MY - Malesia 1
NP - Nepal 1
PT - Portogallo 1
RO - Romania 1
RS - Serbia 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SR - Suriname 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
ZW - Zimbabwe 1
Totale 7.778
Salva come PNG Salva come JPEG
Città #
Southend 549
Singapore 488
Ashburn 299
Chandler 288
Fairfield 230
Hong Kong 181
Beijing 146
Ho Chi Minh City 136
San Jose 136
Houston 135
Ann Arbor 129
Seattle 122
Wilmington 119
Hanoi 116
Woodbridge 112
Princeton 110
Santa Clara 101
Dublin 79
Dong Ket 76
Cambridge 74
Boardman 63
Lauterbourg 55
Nanjing 53
Bern 51
Westminster 50
Padova 49
Lomé 44
Los Angeles 42
Medford 41
Bologna 38
New York 36
Tokyo 35
Helsinki 26
Frankfurt am Main 25
Hebei 25
Abeokuta 24
Hefei 24
Jinan 24
Shenyang 24
Saint Petersburg 23
Haiphong 20
Nanchang 20
Redondo Beach 20
Shanghai 20
Changsha 19
São Paulo 19
Amman 18
Berlin 18
Dallas 18
San Diego 18
Sofia 18
Abidjan 17
Bremen 16
Brussels 16
Florence 16
Tianjin 16
Da Nang 15
Guangzhou 14
Buffalo 13
Turin 13
Falls Church 12
Hangzhou 10
Milan 10
Ningbo 10
Jiaxing 9
Munich 9
Norwalk 9
Seoul 9
Hyderabad 8
Hải Dương 8
London 8
Mountain View 8
Paris 8
Redwood City 8
Toronto 8
Johannesburg 7
Las Vegas 7
Baghdad 6
Bangkok 6
Brooklyn 6
Can Tho 6
Dearborn 6
Düsseldorf 6
Fuzhou 6
Lanzhou 6
Tehran 6
Xi'an 6
Zhengzhou 6
Amsterdam 5
Council Bluffs 5
Haikou 5
Kunming 5
Manila 5
Mashhad 5
Mumbai 5
Mülheim 5
Nuremberg 5
Orem 5
Phoenix 5
Roubaix 5
Totale 4.996
Salva come PNG Salva come JPEG
Nome #
CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients. 256
Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR) 234
Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: A new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients 227
ARF Loss, a Negative Prognostic Factor in Philadelphia-Positive Acute Lymphoblastic Leukemia, May Be Efficiently Overcome by the Small Molecule MDM2 Antagonist RG7112 227
Use of a High Sensitive Nanofluidic Array for the Detection of Rare Copies of BCR-ABL1 Transcript In Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (ALL). 219
The Novel Small Molecule Chk1/Chk2 Inhibitor PF-0477736 (Pfizer) Is Highly Active As Single Agent in Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) 219
Inhibition of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) is a novel therapeutic strategy in B- and T-Acute Lymphoblastic Leukemia (ALL). 214
RALE051: a novel established cell line of sporadic Burkitt lymphoma 209
A germline polymorphism in the ANRIL (CDKN2BAS) locus is associated with susceptibility to Philadelphia-positive acute lymphoblastic leukemia (ALL) 204
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 192
DEEP MOLECULAR CHARACTERIZATION OF ADULT B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BC-ALL) NEGATIVE FOR RECURRENT FUSION GENES REVEALS A HIGH COMPLEX GENETIC HETEROGENEITY INFLUENCING PROGNOSIS 190
SIRPB1 Is a Strong Predictor Biomarker of Response to 5-Azacitidine Therapy in MDS and AML Patients 189
Inhibition of DNA repair by the small molecule Chk1/Chk2 inhibitor PF-0477736 (Pfizer) in B-acute lymphoblastic leukemia (ALL) 187
TP53 mutations are mutually exclusive with FLT3 and NPM mutations in AML patients and are strongly associated with complex karyotype and poor outcome 177
TP53 Alterations Including Missense Mutations, Aberrant Exon-Junctions and Internal Intron Retentions Are Frequent and May Contribute to MDM2 Antagonist-Resistance in B-Acute Lymphoblastic leukemia 175
Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients 172
Down-Regulation of BMI-1 Is a New Marker of Sensitivity to Mdm2 Inhibition in B-Acute Lymphoblastic Leukemia. 172
Mesenchymal stromal cells (MSCs) induce ex vivo proliferation and erythroid commitment of cord blood haematopoietic stem cells (CB-CD34+ cells) 165
In Vitro and in Vivo Single-Agent Efficacy of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) Inhibitor PF-0477736 (Pfizer) in B- and T-Acute Lymphoblastic Leukemia (ALL) 165
Down-Regulation of BMI-1 Is a New Marker of Sensitivity to Mdm2 Inhibition in B-Acute Lymphoblastic Leukemia. 163
Gas1 and Kif27 genes are strongly up-regulated biomarkers of Hedgehog inhibition (PF-04449913) on leukemia stem cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia treated patients 163
GENETIC VARIATIONS IN ADH1A AND CYP2E1 STRONGLY AFFECTS RESPONSE AND TOXICITY TO A COMBINATION OF GEMTUZUMAB OZOGAMICIN PLUS FLUDARABINE, CYTARABINE, IDARUBICIN IN CD33-POSITIVE ACUTE MYELOID LEUKEMIA (AML) PATIENTS 161
THE RS564398, A POLYMORPHISM IN “THE ANTISENSE NON-CODING RNA IN THE INK4 LOCUS”, ANRIL, IS ASSOCIATED TO PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) SUSCEPTIBILITY 161
Digital PCR (dPCR) Overcomes the Limitations in Detection and in Quantification of Quantitative PCR (qPCR) and Reveals Different Levels of BCR-ABL1 Copies/µl Among the Chronic Myeloid Leukemia (CML) Patients Achieving Major (MR3.0) or DEEP (MR4.0, MR4.5 and MR5.0) Molecular Response with Tyrosin Kynase Inhibitors (TKIs) 161
Use of a high sensitive nanofluidic array for the detection of rare copies of BCR-ABL1 transcript in patients with Philadelphia-positive acute lymphoblastic leukemia in complete response 160
GAS1 AND KIF27 GENES ARE STRONGLY UP-REGULATED BIOMARKERS OF HEDGEHOG INHIBITION (PF-04449913) ON LEUKEMIA STEM CELLS IN PHASE I ACUTE MYELOID LEUKEMIA AND CHRONIC MYELOID LEUKEMIA TREATED PATIENTS 159
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 159
Tp53 mutation screening in adult acute myeloid leukemia (AML) patients shows a strong association with complex karyotype and poor outcome 158
NEXT GENERATION PAIRED END TRANSCRIPTOMIC RE-SEQUENCING TECHNOLOGY REVEALS NOVEL COMMON GENETIC ALTERATIONS IN THE HEDGEHOG PATHWAY IN ADULT BCR-ABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 155
Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin 154
MULTIPLEX PCR TO RAPIDLY IDENTIFY IKZF1 (IKAROS) GENE BREAKPOINTS IN BCRABL1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 152
LOSS OF CDKN2A GENE IS A POOR PROGNOSTIC MARKER IN ADULT BCR-ABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS 148
Ultra-Deep Sequencing Strategy Is a Precious Tool to Find Small Clones Harbouring FLT3 Mutations in AML Patients 145
PF-04449913 Reverts Multi Drug Resistance (MDR) by a Strong Down-Regulation of ABCA2 and BCL2 on Leukemia Stem Cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia Treated Patients 144
SEVERAL FUSION TRANSCRIPTS ARE DETECTED BY NEXT GENERATION PAIRED END TRANSCRIPTOMIC RE-SEQUENCING APPROACH IN ADULT BCR-ABL1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 141
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 141
Resistance to second-line tyrosine kinase inhibitor treatment in imatinib-resistant Philadelphia-positive leukemia patients can be anticipated by ultra-deep sequencing of the BCR-ABL kinase domain using Roche 454 technology 139
Loss of Heterozygosity At the C Wild-Type Allele of rs1042522 in the TP53 Gene Frequently Occurs During Progression of Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL) 136
High Sensitivity Mutation Screening and Clonal Analysis Allowed by Ultra-Deep Amplicon Sequencing Uncover the Complexity of Bcr-Abl Mutation Status in Patients Treated with Tyrosine Kinase Inhibitors 135
The Small Molecule CHK1/CHK2 Inhibitor PF-0477736 (Pfizer) Demonstrates Single Agent Activity and Synergizes with Chemotherapy in Diffuse Large B-Cell Lymphoma 135
The role of the loss of CDKN2A gene on prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia (ALL) 132
PF-04449913 reverts multi drug resistance (MDR) by a strong down-regulation of ABCA2 and BCL2 on leukemia stem cells in phase I acute myeloid leukemia and chronic myeloid leukemia treated patients 128
Molecular characterization of TP53 mutations in B-acute lymphoblastic leukemia (B-ALL) reveals missense substitutions, aberrant exon-junctions and intron retention events 126
Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain Allows Earlier Detection and More Accurate Characterization of Resistant Subclones in Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Receiving Tyrosine Kinase Inhibitor-Based Therapies 125
SET-UP OF A MULTIPLEX PCR TO RAPIDLY DETECT IKZF1 (IKAROS) GENE BREAKPOINT DELETION IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 116
The small molecule CHK1/CHK2 inhibitor PF-0477736 (Pfizer) demonstrates single agent activity in diffuse large B-cell lymphoma 111
Loss of the tumor suppressor genes CDKN2A/ARF impairs prognosis in adult BCR-ABL1 positive acute lymphoblastic leukemia (ALL) 110
PROSPECTIVE PHASE II STUDY ON LOW-DOSE 5-AZACYTIDINE FOR TREATMENT OF SYMPTOMATIC PATIENTS WITH LOW/INT-1 RISK MYELODISPLASIA 100
Totale 7.911
Salva come PNG Salva come JPEG
Categoria #
all - tutte 20.605
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.605
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021183 0 0 0 0 0 0 0 0 0 0 0 183
2021/2022912 64 13 64 67 106 69 13 48 46 78 156 188
2022/20231.177 168 190 42 156 85 89 31 75 160 14 81 86
2023/2024269 13 49 8 30 16 56 19 16 19 12 11 20
2024/2025981 55 170 88 70 152 35 59 12 13 106 14 207
2025/20262.248 154 151 169 125 280 132 228 98 565 220 84 42
Totale 7.911